Abstract
Ximelagatran is a prodrug that is rapidly converted to melagatran, a direct, competitive and reversible inhibitor of the active site of human α-thrombin. Its effect is independent from diet, plasma antithrombin levels, obesity or ethnicity. It has little effect on bleeding time at doses up to twice those required, and interference with other drugs is avoided by the absence of interaction with cytochrome P450. Ximelagatran has been documented in a large clinical programme with proven efficacy in prevention and treatment of venous thromboembolism, prevention of stroke in patients with atrial fibrillation and prevention of major cardiovascular events following a recent myocardial infarction. Bleeding has not been a problem, but increase in liver enzymes is a cause of concern for long term use until more information is available.
Keywords: Antithrombotic agent, thrombosis, coagulation, oral anticoagulant therapy
Letters in Drug Design & Discovery
Title: Ximelagatran: An Oral Direct Thrombin Inhibitor for Anticoagulant Therapy
Volume: 2 Issue: 7
Author(s): Marco L. Rossi, Dennis Zavalloni, Guido Belli and Patrizia Presbitero
Affiliation:
Keywords: Antithrombotic agent, thrombosis, coagulation, oral anticoagulant therapy
Abstract: Ximelagatran is a prodrug that is rapidly converted to melagatran, a direct, competitive and reversible inhibitor of the active site of human α-thrombin. Its effect is independent from diet, plasma antithrombin levels, obesity or ethnicity. It has little effect on bleeding time at doses up to twice those required, and interference with other drugs is avoided by the absence of interaction with cytochrome P450. Ximelagatran has been documented in a large clinical programme with proven efficacy in prevention and treatment of venous thromboembolism, prevention of stroke in patients with atrial fibrillation and prevention of major cardiovascular events following a recent myocardial infarction. Bleeding has not been a problem, but increase in liver enzymes is a cause of concern for long term use until more information is available.
Export Options
About this article
Cite this article as:
Rossi L. Marco, Zavalloni Dennis, Belli Guido and Presbitero Patrizia, Ximelagatran: An Oral Direct Thrombin Inhibitor for Anticoagulant Therapy, Letters in Drug Design & Discovery 2005; 2 (7) . https://dx.doi.org/10.2174/157018005774479168
DOI https://dx.doi.org/10.2174/157018005774479168 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ambulatory Blood Pressure Monitoring in Type 2 Diabetes Mellitus: A Cross-sectional Study
Current Hypertension Reviews Early Functional and Structural Microvascular Changes in Hypertension Related to Aging
Current Hypertension Reviews Search for Obesity Drugs: Targeting Central and Peripheral Pathways
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Atopic Dermatitis in the Elderly
Inflammation & Allergy - Drug Targets (Discontinued) In vitro Vasorelaxant Effect of Artemisia herba alba Asso. in Spontaneously Hypertensive Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiovascular Risk Prediction using JBS3 Tool: A Kerala based Study
Current Medical Imaging Adherence to Secondary Prophylaxis for Acute Rheumatic Fever and Rheumatic Heart Disease: A Systematic Review
Current Cardiology Reviews Impaired Cerebral Autoregulation and Vasomotor Reactivity in Sporadic Alzheimer’s Disease
Current Alzheimer Research Recent Advances in the Discovery and Development of Direct Coagulation Factor Xa Inhibitors
Current Pharmaceutical Design Homocysteine Enhances Transmigration of Rat Monocytes through a Brain Capillary Endothelial Cell Monolayer via ICAM-1
Current Neurovascular Research Adrenomedullin in Vascular Endothelial Injury and Combination Therapy: Time for a New Paradigm
Current Vascular Pharmacology High-Yield Biocatalytic Amination Reactions in Organic Synthesis
Current Organic Chemistry Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker
Cardiovascular & Hematological Agents in Medicinal Chemistry Analysis of Chemical Composition by GC-MS and In-vitro Antidiabetic Activity of Azadirachta Indica Leaves Collected from Erbil, Iraq
Current Traditional Medicine Antihypertensive Treatments in Patients Affected by Aortic Valve Stenosis
Current Pharmaceutical Design Ulnar Artery Thrombosis Due to Hypothenar Hammer Syndrome
Recent Patents on Cardiovascular Drug Discovery Improved Lipid Target Level Attainment in Patients with Peripheral Artery Disease
Current Vascular Pharmacology Covid-19 in Man: A Very Dangerous Affair
Endocrine, Metabolic & Immune Disorders - Drug Targets Alzheimers Disease: From Pathogenesis to Disease-Modifying Approaches
CNS & Neurological Disorders - Drug Targets Human Embryonic and Induced Pluripotent Stem Cells in Cardiovascular Drug Discovery: Patents and Patented Uses
Recent Patents on Cardiovascular Drug Discovery